Discovery of a novel inhibitor of macropinocytosis with antiviral activity
Ver/ Abrir
Registro completo
Mostrar el registro completo DCAutoría
Porebski, Bartlomiej; Christ, Wanda; Corman, Alba; Haraldsson, Martin; Barz, Myriam; Lidemalm, Louise; Häggblad, Maria; Ilmain, Juliana; Wright, Shane C.; Murga, Matilde; Schlegel, Jan; Jarvius, Malin; Lapins, Maris; Sezgin, Erdinc; Bhabha, Gira; Lauschke, Volker M.; Carreras-Puigvert, Jordi; Lafarga Coscojuela, Miguel Ángel
Fecha
2024Derechos
© 2024 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy. This is an open access article under the CC BY-NC-ND license.
Publicado en
Molecular Therapy, 2024, 39(9), 3012-3024
Editorial
Academic Press/Cell Press
Enlace a la publicación
Palabras clave
Antivirals
Drug development
Chemical screen
SARS-CoV-2
Mpox virus
Tick-borne encephalitis virus
Pseudotype virus
Macropinocytosis
Resumen/Abstract
Several viruses hijack various forms of endocytosis in order to infect host cells. Here, we report the discovery of a molecule with antiviral properties that we named virapinib, which limits viral entry by macropinocytosis. The identification of virapinib derives from a chemical screen using high-throughput microscopy, where we identified chemical entities capable of preventing infection with a pseudotype virus expressing the spike (S) protein from SARS-CoV-2. Subsequent experiments confirmed the capacity of virapinib to inhibit infection by SARS-CoV-2, as well as by additional viruses, such as mpox virus and TBEV. Mechanistic analyses revealed that the compound inhibited macropinocytosis, limiting this entry route for the viruses. Importantly, virapinib has no significant toxicity to host cells. In summary, we present the discovery of a molecule that inhibits macropinocytosis, thereby limiting the infectivity of viruses that use this entry route such as SARS-CoV2.
Colecciones a las que pertenece
- D01 Artículos [119]
- IDIVAL Artículos [864]